Miami, FL -- (ReleaseWire) -- 01/20/2014 -- Pennystocksites.com a leading online financial newsletter source, Reports on the following Companies: Datalink Corporation (NASDAQ:DTLK), 3D Eye Solutions, Inc. (OTCMKTS:TDEY), Sirius XM Holdings Inc. (NASDAQ:SIRI) and Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN).
Every day we scan the markets for the hottest stocks with the best potential for huge gains. Our vast network is second to none when it comes to delivering fast moving stocks and more importantly getting you out in front of them.
Join Us Here: http://pennystocksites.com/
Datalink Corporation (NASDAQ:DTLK), Datalink Corporation engages in the design, installation, and support of data center solutions to mid and large-size companies. It is involved in assessing, designing, deploying, managing, and supporting unified infrastructures, such as servers, storage, and networks; and reselling hardware and software from original equipment manufacturers. The companys portfolio of solutions and services comprise consolidation and virtualization services that enable organizations to share server and storage resources; and data storage and protection services, including network-attached, direct-attached, private cloud-based storage, local and remote backup, disaster recovery, archive, and compliance. It also offers network infrastructure review services, which include an assessment of a customer's current network design, recommendations for improvement, and a roadmap for migrating to consolidated and converged network; contracts administration services; and business continuity and disaster recovery solutions. In addition, the company offers a suite of practice-specific consulting, analysis, design, implementation, management, and support services. Datalink Corporation provides its solutions through direct sales force in the United States. The company was founded in 1958 and is headquartered in Eden Prairie, Minnesota.
Get a Free Technical Analysis on Datalink Corporation (NASDAQ:DTLK): http://pennystocksites.com/market-scan/?symbol=dtlk
3D Eye Solutions, Inc. (OTCMKTS:TDEY), 3D Eye Solutions, Inc. engages in developing, providing, and integrating content conversion service for the 3D stereo and auto-stereo media industry in the United States. The company offers 3D Eye Solutions conversion technology that supports education by converting older DVD video content libraries to deliver content for use. Its 3D Eye Solutions include 3D Eye Solutions auto-stereoscopic displays to enhance the viewer’s visual experience without the need for 3D glasses or special eyewear; and 3D Eye Media Module, an integrated hardware and software solution for the plug and play individuals. The company also provides auto-stereoscopic systems for high traffic venues, such as malls and shopping centers, airports, convention centers, concerts, and sport events; and corporate applications, including lobbies, conference, sales presentations, and trade show events. In addition, it offers Reality Splitter, a conversion technology process for cinema, digital signage, and home theater markets. Further, the company provides platform for content creation, management, and distribution in digital signage networks that are used in retail, education, entertainment, government, and other industries for various applications, such as retail advertising networks, corporate communications, traditional and digital billboards, digital menu boards, digital posters, cable TV, hotel lobby signage, gas pump toppers, outdoor advertising, interactive kiosks, etc. 3D Eye Solutions, Inc. was incorporated in 1992 and is based in Mount Dora, Florida.
Get a Free Technical Analysis on 3D Eye Solutions, Inc. (OTCMKTS:TDEY): http://pennystocksites.com/market-scan/?symbol=tdey
Sirius XM Holdings Inc. (NASDAQ:SIRI), Sirius XM Holdings Inc. provides satellite radio services in the United States and Canada. The company creates and broadcasts commercial-free music; sports talk and live events; comedy; news; exclusive talk and entertainment; and the comprehensive Latin music, sports, and talk programming in radio. It also provides traffic, weather, data, and information services for subscribers in cars, trucks, RVs, boats, and aircraft through SiriusXM Traffic, SiriusXM Travel Link, NavTraffic, NavWeather, SiriusXM Aviation, SiriusXM Marine, Sirius Marine Weather, XMWX Aviation, and XMWX Marine. In addition, the company offers SiriusXM programming through the SiriusXM Internet Radio App for smartphones and other connected devices, as well as online at siriusxm.com. It provides telematics and connected vehicles services, such as safety, security, and convenience services to various automotive manufacturers. The company’s satellite radios are primarily distributed through automakers and retailers, as well as through its Website. As of November 19, 2013, it had approximately 25.6 million subscribers. The company was formerly known as Sirius XM Radio Inc. and changed its name to Sirius XM Holdings Inc. in November 2013. Sirius XM Holdings Inc. was founded in 1990 and is headquartered in New York, New York.
Get a Free Technical Analysis on Sirius XM Holdings Inc. (NASDAQ:SIRI): http://dailymarketreporter.com/market-scan/?symbol=siri
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt-1, which has completed a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as is focusing on initiating Phase IIa clinical trials for chemo-resistant solid tumors and hematological malignancies; RX-3117, which has completed an exploratory Phase I clinical study in humans with therapeutic potential in a range of cancers, including colon, lung, and pancreatic cancer; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase and focuses on initiating Phase I clinical trials. The company’s pre-clinical pipeline consist of RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, nano-polymer anticancer. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Get a Free Technical Analysis on Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): http://pennystocksites.com/market-scan/?symbol=rnn
We are not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit http://pennystocksites.com/disclaimer/ for complete risks and disclosures.